Hospital
Kaiser Foundation Hospitals
Kaiser Foundation Hospitals was paid $83.04M by Medicaid between Jan 2018 and Dec 2024, across 395 billing codes. Its largest line is 99283, emergency room visit (moderate) — 35% of everything it billed.
33Billing provider infoKAISER FOUNDATION HOSPITALS
LOS ANGELES, CA 90034
LOS ANGELES, CA 90034
33aNPI1134274897assigned 01/24/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$83.04M
24GClaims2,241,387
24DCodes billed395
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#31 of 410
Median peer was paid$6.90M
This provider vs. median12×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 219,783 | $1.19M | |
| 2019 | 296,594 | $11.50M | |
| 2020 | 249,419 | $12.97M | |
| 2021 | 316,233 | $11.19M | |
| 2022 | 342,941 | $13.35M | |
| 2023 | 390,152 | $15.37M | |
| 2024incomplete | 426,265 | $17.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 35% | 64,971 | 58,877 | $28.90M |
| G0378 | Hospital observation service, per hour | 8.5% | 5,814 | 3,665 | $7.05M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.0% | 7,804 | 7,502 | $5.78M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.6% | 9,733 | 9,559 | $3.01M |
| 0450 | Emergency room services | 3.2% | 62,123 | 55,946 | $2.69M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 8,899 | 8,683 | $2.25M |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | 2.2% | 2,140 | 2,091 | $1.82M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.4% | 4,059 | 3,707 | $1.18M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 11,261 | 10,989 | $1.17M |
| 71045 | Radiologic examination, chest; single view | 1.3% | 22,822 | 21,389 | $1.05M |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.1% | 17,894 | 17,198 | $884K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.0% | 533 | 531 | $834K |
383 more codes
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,637 | $663K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,026 | $658K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 7,595 | $629K |
| 76830 | Ultrasound, transvaginal | <1% | 7,235 | $594K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 12,024 | $577K |
| 80051 | <1% | 112,376 | $518K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17,619 | $514K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17,635 | $514K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 104,550 | $514K |
| 82565 | <1% | 131,995 | $504K | |
| 86900 | <1% | 10,256 | $487K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 2,263 | $478K |
| 86885 | <1% | 7,118 | $463K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 28,793 | $456K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 4,845 | $406K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 1,054 | $398K |
| 93971 | <1% | 2,052 | $395K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 41,567 | $388K |
| 83880 | <1% | 15,919 | $353K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,727 | $349K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 11,375 | $339K |
| 80061 | Lipid panel | <1% | 25,917 | $339K |
| 84460 | <1% | 73,299 | $329K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,734 | $326K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,408 | $309K |
| 73562 | <1% | 5,276 | $303K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 14,782 | $295K |
| 73630 | <1% | 5,235 | $286K | |
| 78451 | <1% | 231 | $276K | |
| 76641 | <1% | 2,893 | $269K | |
| 83970 | <1% | 5,736 | $256K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 11,878 | $255K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 220 | $248K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,246 | $247K |
| 85027 | <1% | 48,049 | $245K | |
| 73030 | <1% | 4,254 | $237K | |
| 73610 | <1% | 4,325 | $228K | |
| 93017 | <1% | 522 | $202K | |
| 72100 | <1% | 2,463 | $196K | |
| 82247 | <1% | 51,259 | $194K | |
| 84702 | <1% | 20,769 | $192K | |
| 84520 | <1% | 87,953 | $185K | |
| 73130 | <1% | 3,501 | $182K | |
| 76770 | <1% | 1,901 | $179K | |
| 76536 | <1% | 1,808 | $178K | |
| 82728 | <1% | 12,926 | $178K | |
| 86780 | <1% | 14,524 | $178K | |
| 84075 | <1% | 45,759 | $176K | |
| 81513 | <1% | 2,053 | $173K | |
| 93970 | <1% | 712 | $172K | |
| 70486 | <1% | 1,365 | $166K | |
| 82947 | <1% | 78,847 | $164K | |
| 84450 | <1% | 42,846 | $163K | |
| 71250 | <1% | 1,275 | $163K | |
| 99199 | Unlisted special service, procedure or report | <1% | 4,612 | $156K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,641 | $154K |
| 86901 | <1% | 10,275 | $152K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 9,802 | $151K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 3,393 | $147K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 730 | $145K |
| 73110 | <1% | 2,697 | $144K | |
| 86141 | <1% | 11,758 | $142K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,981 | $136K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 4,040 | $135K |
| 87505 | <1% | 1,196 | $135K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,563 | $134K |
| 86803 | <1% | 8,889 | $121K | |
| 82310 | <1% | 29,871 | $120K | |
| 72141 | <1% | 592 | $120K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 12,877 | $119K |
| 86923 | <1% | 692 | $116K | |
| 83690 | <1% | 28,026 | $115K | |
| 84484 | <1% | 28,155 | $113K | |
| 83550 | <1% | 13,024 | $113K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 495 | $107K |
| 82607 | <1% | 7,063 | $106K | |
| 85610 | <1% | 33,490 | $105K | |
| 73502 | <1% | 1,759 | $105K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 417 | $103K |
| 86480 | <1% | 1,585 | $103K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 760 | $100K |
| 72170 | <1% | 1,222 | $97K | |
| 87088 | <1% | 19,795 | $96K | |
| 0637 | <1% | 93,782 | $95K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 6,868 | $95K |
| 73140 | <1% | 1,866 | $93K | |
| 87340 | <1% | 10,124 | $93K | |
| 81003 | <1% | 54,468 | $92K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,199 | $92K |
| 83735 | <1% | 19,228 | $87K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 869 | $87K |
| 87536 | <1% | 1,111 | $87K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 27,443 | $84K |
| 74018 | <1% | 1,603 | $84K | |
| 83540 | <1% | 13,111 | $79K | |
| 70496 | <1% | 333 | $79K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 3,372 | $78K |
| 87481 | <1% | 2,084 | $78K | |
| 82043 | <1% | 12,225 | $78K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 2,046 | $77K |
| 84153 | <1% | 4,072 | $73K | |
| 77080 | <1% | 478 | $71K | |
| 73564 | <1% | 699 | $69K | |
| 82040 | <1% | 14,862 | $68K | |
| 70498 | <1% | 290 | $67K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 512 | $64K |
| 93880 | <1% | 201 | $63K | |
| 73080 | <1% | 1,279 | $63K | |
| 83520 | <1% | 3,521 | $62K | |
| 84403 | <1% | 2,423 | $61K | |
| 77066 | Tomosynthesis, mammo | <1% | 467 | $55K |
| 90686 | <1% | 4,283 | $55K | |
| 76881 | <1% | 514 | $54K | |
| 86003 | <1% | 1,126 | $53K | |
| 70491 | <1% | 273 | $53K | |
| 84439 | <1% | 6,169 | $51K | |
| 82746 | <1% | 3,399 | $50K | |
| 87040 | <1% | 11,325 | $49K | |
| 76870 | <1% | 584 | $48K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 438 | $48K |
| 77065 | Tomosynthesis, mammo | <1% | 533 | $47K |
| 73590 | <1% | 949 | $47K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,466 | $45K |
| 82248 | <1% | 15,885 | $44K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 1,097 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,244 | $43K |
| 83021 | <1% | 2,609 | $43K | |
| 84100 | <1% | 11,909 | $42K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 600 | $41K |
| P9021 | Red blood cells, each unit | <1% | 583 | $41K |
| 72040 | <1% | 786 | $39K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,848 | $39K |
| 82570 | <1% | 6,584 | $38K | |
| 83605 | <1% | 8,115 | $38K | |
| 86762 | <1% | 2,789 | $37K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 365 | $36K |
| 82105 | <1% | 2,123 | $36K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,111 | $36K |
| 85652 | <1% | 14,309 | $36K | |
| 87210 | <1% | 9,510 | $35K | |
| 83721 | <1% | 3,469 | $35K | |
| 86787 | <1% | 2,895 | $34K | |
| 71101 | <1% | 415 | $32K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 7,074 | $31K |
| 73560 | <1% | 631 | $30K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,343 | $30K |
| 86038 | <1% | 2,464 | $28K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 411 | $28K |
| 84165 | <1% | 2,375 | $28K | |
| 82784 | <1% | 1,253 | $28K | |
| Z7502 | <1% | 1,271 | $28K | |
| 82670 | <1% | 916 | $27K | |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 2,262 | $26K |
| 86704 | <1% | 2,176 | $25K | |
| 83001 | <1% | 1,430 | $25K | |
| 86317 | <1% | 1,744 | $25K | |
| 80306 | <1% | 2,429 | $25K | |
| 84146 | <1% | 1,349 | $25K | |
| 83655 | <1% | 2,794 | $25K | |
| 84156 | <1% | 6,123 | $24K | |
| 80076 | <1% | 3,103 | $24K | |
| 73090 | <1% | 540 | $24K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,190 | $23K |
| 84132 | <1% | 4,806 | $23K | |
| 82077 | <1% | 3,092 | $22K | |
| 73660 | <1% | 457 | $22K | |
| J3490 | Unclassified drugs | <1% | 6,727 | $21K |
| 82378 | <1% | 1,079 | $21K | |
| 83718 | <1% | 2,719 | $20K | |
| 86360 | <1% | 700 | $19K | |
| 85379 | <1% | 3,452 | $18K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 1,334 | $18K |
| 85730 | <1% | 4,643 | $17K | |
| 76380 | <1% | 222 | $17K | |
| 88342 | <1% | 130 | $17K | |
| 82550 | <1% | 3,520 | $17K | |
| 83615 | <1% | 2,848 | $16K | |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | <1% | 194 | $16K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 4,004 | $15K |
| 86359 | <1% | 699 | $15K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 616 | $15K |
| 80197 | <1% | 984 | $15K | |
| 84550 | <1% | 3,847 | $15K | |
| 86160 | <1% | 685 | $14K | |
| 74183 | <1% | 29 | $14K | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 242 | $14K |
| 84270 | <1% | 629 | $14K | |
| 73100 | <1% | 214 | $13K | |
| 73221 | <1% | 53 | $13K | |
| 97161 | <1% | 854 | $13K | |
| 80179 | <1% | 1,793 | $13K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 354 | $13K |
| 85014 | <1% | 5,008 | $12K | |
| 0250 | <1% | 10,792 | $12K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 536 | $12K |
| 86765 | <1% | 864 | $11K | |
| 90715 | <1% | 423 | $11K | |
| 84134 | <1% | 917 | $11K | |
| 84480 | <1% | 952 | $11K | |
| 82950 | <1% | 2,552 | $11K | |
| 82465 | <1% | 2,816 | $11K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 184 | $10K |
| 74178 | <1% | 24 | $10K | |
| 0258 | <1% | 4,798 | $10K | |
| 84295 | <1% | 2,044 | $10K | |
| 85018 | <1% | 3,471 | $9K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,535 | $9K |
| 72050 | <1% | 99 | $9K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 2,805 | $9K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,819 | $9K |
| J1815 | Injection, insulin, per 5 units | <1% | 3,724 | $9K |
| 86225 | <1% | 630 | $9K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,981 | $9K |
| 71271 | <1% | 58 | $9K | |
| 83002 | <1% | 478 | $8K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 2,807 | $8K |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,102 | $8K |
| 87186 | <1% | 1,808 | $8K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 437 | $8K |
| 86431 | <1% | 1,261 | $7K | |
| 82627 | <1% | 319 | $7K | |
| 85046 | <1% | 1,878 | $7K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 309 | $7K |
| 84163 | <1% | 464 | $7K | |
| 87081 | <1% | 1,654 | $7K | |
| 87449 | <1% | 954 | $7K | |
| 96367 | <1% | 350 | $7K | |
| 81015 | <1% | 1,795 | $6K | |
| 87497 | <1% | 126 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,872 | $6K |
| 72131 | <1% | 44 | $6K | |
| 0710 | <1% | 833 | $6K | |
| 74174 | <1% | 12 | $6K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,953 | $6K |
| 72197 | <1% | 13 | $6K | |
| 87205 | <1% | 2,025 | $6K | |
| 73552 | <1% | 104 | $6K | |
| 86301 | <1% | 296 | $6K | |
| G0008 | Administration of influenza virus vaccine | <1% | 2,038 | $6K |
| 86769 | <1% | 260 | $6K | |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | <1% | 643 | $5K |
| 73060 | <1% | 99 | $5K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,306 | $5K |
| 82677 | <1% | 216 | $5K | |
| 82805 | <1% | 263 | $5K | |
| 82962 | <1% | 2,544 | $5K | |
| 74022 | <1% | 59 | $5K | |
| 86334 | <1% | 177 | $5K | |
| 74181 | <1% | 13 | $4K | |
| 0255 | <1% | 709 | $4K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 46 | $4K |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 974 | $4K |
| 87522 | Neg quan hep c or qual rna | <1% | 105 | $4K |
| 82977 | <1% | 439 | $4K | |
| 84478 | <1% | 735 | $4K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,260 | $4K |
| 86364 | <1% | 282 | $3K | |
| 73523 | <1% | 24 | $3K | |
| 10060 | <1% | 111 | $3K | |
| 86336 | <1% | 216 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 116 | $3K |
| 83921 | <1% | 137 | $3K | |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 951 | $3K |
| 84155 | <1% | 634 | $3K | |
| 82274 | <1% | 172 | $3K | |
| 86376 | <1% | 188 | $3K | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 402 | $3K |
| 72070 | <1% | 38 | $3K | |
| 90662 | <1% | 219 | $3K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,397 | $3K |
| 87517 | <1% | 52 | $2K | |
| 86677 | <1% | 370 | $2K | |
| 87070 | <1% | 510 | $2K | |
| 29125 | <1% | 83 | $2K | |
| 86304 | <1% | 115 | $2K | |
| 90656 | <1% | 178 | $2K | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 765 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,269 | $2K |
| 86256 | <1% | 89 | $2K | |
| 86592 | <1% | 552 | $2K | |
| 99292 | <1% | 12 | $2K | |
| 87631 | <1% | 88 | $2K | |
| 81329 | <1% | 24 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 518 | $2K |
| C1769 | Guide wire | <1% | 45 | $2K |
| 83993 | <1% | 96 | $2K | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 808 | $2K |
| 86255 | <1% | 122 | $2K | |
| 80329 | <1% | 1,007 | $2K | |
| 85045 | <1% | 656 | $2K | |
| 82533 | <1% | 99 | $2K | |
| 84145 | <1% | 233 | $2K | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 155 | $2K |
| 29515 | <1% | 38 | $2K | |
| 76706 | <1% | 13 | $2K | |
| 80320 | <1% | 952 | $2K | |
| 80359 | <1% | 521 | $2K | |
| 86300 | <1% | 56 | $1K | |
| 80324 | <1% | 513 | $1K | |
| 36902 | <1% | 12 | $1K | |
| 0370 | <1% | 814 | $1K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 140 | $1K |
| 86665 | <1% | 80 | $1K | |
| J3371 | Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg | <1% | 91 | $1K |
| 12011 | <1% | 43 | $1K | |
| 77061 | <1% | 12 | $1K | |
| 12001 | <1% | 89 | $1K | |
| 82951 | <1% | 67 | $1K | |
| 86308 | <1% | 235 | $1K | |
| 88307 | <1% | 16 | $998.00 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 850 | $939.05 |
| 82150 | <1% | 145 | $933.39 | |
| 73120 | <1% | 14 | $931.36 | |
| 90674 | <1% | 49 | $912.32 | |
| 86880 | <1% | 18 | $902.54 | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 476 | $880.03 |
| 86709 | <1% | 94 | $879.53 | |
| 73070 | <1% | 14 | $876.54 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 554 | $780.86 |
| 0272 | <1% | 78 | $768.38 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 130 | $746.94 |
| 82140 | <1% | 129 | $737.43 | |
| 90688 | <1% | 111 | $717.79 | |
| 86735 | <1% | 54 | $691.00 | |
| 84425 | <1% | 38 | $681.85 | |
| 86708 | <1% | 54 | $654.67 | |
| 0320 | <1% | 75 | $632.12 | |
| 86140 | <1% | 1,443 | $627.38 | |
| J0456 | Injection, azithromycin, 500 mg | <1% | 298 | $549.06 |
| E0110 | Crutches, forearm, includes crutches of various materials, adjustable or fixed, pair, complete with tips and handgrips | <1% | 12 | $529.63 |
| 86664 | <1% | 40 | $480.90 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 193 | $466.76 |
| 86235 | <1% | 26 | $446.28 | |
| 99499 | <1% | 23 | $420.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 580 | $419.48 |
| 80162 | <1% | 26 | $357.00 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 428 | $346.97 |
| 82103 | <1% | 24 | $316.00 | |
| 87807 | <1% | 27 | $306.86 | |
| 82952 | <1% | 67 | $306.42 | |
| 83010 | <1% | 28 | $298.00 | |
| 86696 | <1% | 13 | $293.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 58 | $292.56 |
| 87255 | <1% | 12 | $290.33 | |
| 86039 | <1% | 27 | $290.00 | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 42 | $250.00 |
| 87324 | <1% | 34 | $240.78 | |
| A0429 | Emergency ambulance ride, basic life support | <1% | 173 | $224.53 |
| 90749 | <1% | 138 | $215.08 | |
| 86695 | <1% | 13 | $208.00 | |
| 82397 | <1% | 13 | $179.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 354 | $163.08 |
| 82164 | <1% | 12 | $163.00 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,320 | $161.53 |
| 87149 | <1% | 15 | $132.68 | |
| 86593 | <1% | 27 | $129.79 | |
| 89051 | <1% | 30 | $117.94 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 129 | $115.23 |
| 88304 | <1% | 114 | $99.50 | |
| 85613 | <1% | 12 | $94.00 | |
| 85660 | <1% | 13 | $86.40 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 18 | $85.86 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 244 | $70.56 |
| 83930 | <1% | 14 | $66.00 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 42 | $51.54 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 29 | $49.43 |
| 82272 | <1% | 12 | $49.00 | |
| 82985 | <1% | 13 | $45.00 | |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 44 | $43.53 |
| 29130 | <1% | 13 | $34.17 | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 14 | $10.00 |
| 3051F | <1% | 395 | $0.01 | |
| 3052F | <1% | 144 | $0.01 | |
| 3046F | 0% | 322 | $0.00 | |
| 3078F | 0% | 136 | $0.00 | |
| 0760 | 0% | 14 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 12 | $0.00 |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | 0% | 13 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 14 | $0.00 |
| 3044F | 0% | 4,092 | $0.00 | |
| 3074F | 0% | 158 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 12 | $0.00 |
| 0771 | 0% | 23 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialZIBARI, LILIT (SVP/AREA MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Kaiser Foundation Hospitals | Los Angeles, CA | $931K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.